JP2017507320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507320A5 JP2017507320A5 JP2016538689A JP2016538689A JP2017507320A5 JP 2017507320 A5 JP2017507320 A5 JP 2017507320A5 JP 2016538689 A JP2016538689 A JP 2016538689A JP 2016538689 A JP2016538689 A JP 2016538689A JP 2017507320 A5 JP2017507320 A5 JP 2017507320A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- prostate cancer
- expression level
- srsf5
- adamts9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 46
- 206010060862 Prostate cancer Diseases 0.000 claims 32
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 32
- 102000051354 ADAMTS9 Human genes 0.000 claims 20
- 108091005669 ADAMTS9 Proteins 0.000 claims 20
- 101000587438 Homo sapiens Serine/arginine-rich splicing factor 5 Proteins 0.000 claims 20
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims 20
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 claims 20
- 102100029703 Serine/arginine-rich splicing factor 5 Human genes 0.000 claims 20
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims 20
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 claims 20
- 239000000523 sample Substances 0.000 claims 20
- 102100034799 CCAAT/enhancer-binding protein delta Human genes 0.000 claims 19
- 102100023344 Centromere protein F Human genes 0.000 claims 19
- -1 ERRI1 Proteins 0.000 claims 19
- 102100022107 Holliday junction recognition protein Human genes 0.000 claims 19
- 101000945965 Homo sapiens CCAAT/enhancer-binding protein delta Proteins 0.000 claims 19
- 101000907941 Homo sapiens Centromere protein F Proteins 0.000 claims 19
- 101001045907 Homo sapiens Holliday junction recognition protein Proteins 0.000 claims 19
- 101001072152 Homo sapiens p53 and DNA damage-regulated protein 1 Proteins 0.000 claims 19
- 102000003620 TRPM3 Human genes 0.000 claims 19
- 108060008547 TRPM3 Proteins 0.000 claims 19
- 102100036350 p53 and DNA damage-regulated protein 1 Human genes 0.000 claims 19
- 102000051388 ADAMTS1 Human genes 0.000 claims 18
- 108091005660 ADAMTS1 Proteins 0.000 claims 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 18
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 18
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 18
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 18
- 101000874532 Homo sapiens Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Proteins 0.000 claims 18
- 101000919269 Homo sapiens cAMP-responsive element modulator Proteins 0.000 claims 18
- 102100035655 Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Human genes 0.000 claims 18
- 102100029387 cAMP-responsive element modulator Human genes 0.000 claims 18
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 claims 17
- 102000000802 Galectin 3 Human genes 0.000 claims 17
- 108010001517 Galectin 3 Proteins 0.000 claims 17
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 claims 17
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims 17
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 claims 17
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 claims 17
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 17
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 17
- 108091007767 MALAT1 Proteins 0.000 claims 17
- 102100031550 Microtubule-associated tumor suppressor 1 Human genes 0.000 claims 17
- 238000004393 prognosis Methods 0.000 claims 17
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims 16
- 101000635965 Homo sapiens Myosin-binding protein C, slow-type Proteins 0.000 claims 16
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims 16
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims 16
- 102100030735 Myosin-binding protein C, slow-type Human genes 0.000 claims 16
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims 16
- 101710148753 Ornithine aminotransferase Proteins 0.000 claims 16
- 102100027177 Ornithine aminotransferase, mitochondrial Human genes 0.000 claims 16
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 15
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 claims 15
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 claims 15
- 101000708222 Homo sapiens Ras and Rab interactor 2 Proteins 0.000 claims 15
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 claims 15
- 101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 claims 15
- 102100027798 Krueppel-like factor 10 Human genes 0.000 claims 15
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 claims 15
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 15
- 102100031490 Ras and Rab interactor 2 Human genes 0.000 claims 15
- 108091006593 SLC15A2 Proteins 0.000 claims 15
- 102100021488 Solute carrier family 15 member 2 Human genes 0.000 claims 15
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 claims 15
- 102100037168 Transcription factor JunB Human genes 0.000 claims 15
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 14
- 102100023471 E-selectin Human genes 0.000 claims 14
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims 14
- 101001125858 Homo sapiens Peptidase inhibitor 15 Proteins 0.000 claims 14
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 claims 14
- 102100029323 Peptidase inhibitor 15 Human genes 0.000 claims 14
- 101150043341 Socs3 gene Proteins 0.000 claims 14
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims 14
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 claims 14
- 102100035804 Zinc finger protein 823 Human genes 0.000 claims 14
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 claims 13
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 claims 13
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 13
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 claims 13
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims 13
- 108091058560 IL8 Proteins 0.000 claims 13
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 13
- 102000004890 Interleukin-8 Human genes 0.000 claims 13
- 108090001007 Interleukin-8 Proteins 0.000 claims 13
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 claims 13
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims 13
- 238000012512 characterization method Methods 0.000 claims 13
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims 12
- 102100029329 Somatostatin receptor type 1 Human genes 0.000 claims 12
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims 12
- 108010082379 somatostatin receptor type 1 Proteins 0.000 claims 12
- 101000666607 Homo sapiens Rho-related BTB domain-containing protein 3 Proteins 0.000 claims 11
- 102100038342 Rho-related BTB domain-containing protein 3 Human genes 0.000 claims 11
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 238000001959 radiotherapy Methods 0.000 claims 9
- 102100031856 ERBB receptor feedback inhibitor 1 Human genes 0.000 claims 8
- 101000920812 Homo sapiens ERBB receptor feedback inhibitor 1 Proteins 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims 6
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 6
- 206010027476 Metastases Diseases 0.000 claims 6
- 230000009401 metastasis Effects 0.000 claims 6
- 238000012360 testing method Methods 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000004883 computer application Methods 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 238000010837 poor prognosis Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 238000003860 storage Methods 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000003559 RNA-seq method Methods 0.000 claims 2
- 101100420168 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RTG2 gene Proteins 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 2
- 229960000853 abiraterone Drugs 0.000 claims 2
- 230000003388 anti-hormonal effect Effects 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004590 computer program Methods 0.000 claims 2
- 230000004049 epigenetic modification Effects 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 102100036126 60S ribosomal protein L37a Human genes 0.000 claims 1
- 102100040079 A-kinase anchor protein 4 Human genes 0.000 claims 1
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 claims 1
- 101001005314 Arabidopsis thaliana Ceramide synthase LOH2 Proteins 0.000 claims 1
- 102100028797 Calsyntenin-2 Human genes 0.000 claims 1
- 101100022254 Candida albicans MAL2 gene Proteins 0.000 claims 1
- 101001138445 Conus striatus Omega-conotoxin SO-3 Proteins 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 claims 1
- 101000916406 Homo sapiens Calsyntenin-2 Proteins 0.000 claims 1
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 claims 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 1
- 101100462419 Homo sapiens OTUB2 gene Proteins 0.000 claims 1
- 101001071233 Homo sapiens PHD finger protein 1 Proteins 0.000 claims 1
- 101000612397 Homo sapiens Prenylcysteine oxidase 1 Proteins 0.000 claims 1
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 claims 1
- 101000648652 Homo sapiens Transmembrane gamma-carboxyglutamic acid protein 1 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 101100446038 Mus musculus Fabp5 gene Proteins 0.000 claims 1
- 101100156417 Mus musculus Lcn3 gene Proteins 0.000 claims 1
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical group C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 101100067506 Oryza sativa subsp. japonica G1 gene Proteins 0.000 claims 1
- 102100036879 PHD finger protein 1 Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 101000587791 Panax ginseng Squalene monooxygenase SE2 Proteins 0.000 claims 1
- 230000026279 RNA modification Effects 0.000 claims 1
- 101100420762 Schizophyllum commune SC6 gene Proteins 0.000 claims 1
- 101000761220 Streptomyces clavuligerus Clavaminate synthase 2 Proteins 0.000 claims 1
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 claims 1
- 102100028865 Transmembrane gamma-carboxyglutamic acid protein 1 Human genes 0.000 claims 1
- 102100025914 Ubiquitin thioesterase OTUB2 Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 101150083490 mal1 gene Proteins 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229920001420 poly(caprolactone-co-lactic acid) Polymers 0.000 claims 1
- 230000009145 protein modification Effects 0.000 claims 1
- 108090000850 ribosomal protein S14 Proteins 0.000 claims 1
- 102000004314 ribosomal protein S14 Human genes 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322034.8 | 2013-12-12 | ||
| GBGB1322034.8A GB201322034D0 (en) | 2013-12-12 | 2013-12-12 | Prostate cancer classification |
| PCT/GB2014/053694 WO2015087088A2 (en) | 2013-12-12 | 2014-12-12 | Prostate cancer classification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507320A JP2017507320A (ja) | 2017-03-16 |
| JP2017507320A5 true JP2017507320A5 (enExample) | 2018-01-25 |
Family
ID=50030858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538689A Pending JP2017507320A (ja) | 2013-12-12 | 2014-12-12 | 前立腺癌分類 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10196697B2 (enExample) |
| EP (1) | EP3080293B1 (enExample) |
| JP (1) | JP2017507320A (enExample) |
| KR (1) | KR20160098351A (enExample) |
| CN (1) | CN105940117A (enExample) |
| AU (1) | AU2014363173A1 (enExample) |
| BR (1) | BR112016013182A2 (enExample) |
| CA (1) | CA2932553A1 (enExample) |
| GB (1) | GB201322034D0 (enExample) |
| IL (1) | IL246067A0 (enExample) |
| MX (1) | MX2016007333A (enExample) |
| SG (1) | SG11201604508PA (enExample) |
| WO (1) | WO2015087088A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2885640B1 (en) | 2012-08-16 | 2018-07-18 | Genomedx Biosciences, Inc. | Prostate cancer prognostics using biomarkers |
| US11174518B2 (en) * | 2015-10-05 | 2021-11-16 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| WO2017112860A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers |
| AU2017209307B2 (en) * | 2016-01-20 | 2023-06-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening and identifying clinically aggressive prostate cancer |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| CA3055925A1 (en) * | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
| WO2019195658A1 (en) * | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| KR20210122275A (ko) * | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| GB201917428D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Newcastle | Prostate cancer diagnostic |
| CN111518908B (zh) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途 |
| EP3960877A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject |
| EP3960876A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes |
| EP3960878A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Selection of a dose for radiotherapy of a prostate cancer subject |
| JP7477872B2 (ja) * | 2020-09-30 | 2024-05-07 | 国立大学法人大阪大学 | 癌に関連する新規バイオマーカー |
| CN113234820A (zh) * | 2021-04-29 | 2021-08-10 | 北京艾克伦医疗科技有限公司 | 鉴定前列腺癌状态的方法和试剂盒 |
| US20250109442A1 (en) * | 2022-01-13 | 2025-04-03 | Oslo Universitetssykehus Hf | Prostate cancer markers and uses thereof |
| EP4253567A1 (en) * | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| CA3253049A1 (en) * | 2022-05-12 | 2023-11-16 | Veracyte, Inc. | PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATIC CANCER |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
| CA2005589C (en) | 1988-12-16 | 2001-02-06 | Akzo Nobel Nv | Self-sustained, sequence replication system |
| US5437975A (en) | 1991-02-25 | 1995-08-01 | California Institute Of Biological Research | Consensus sequence primed polymerase chain reaction method for fingerprinting genomes |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| AU2002214576A1 (en) | 2000-10-13 | 2002-04-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genes related to development of refractory prostate cancer |
| CA2429722A1 (en) * | 2000-11-28 | 2002-06-06 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| WO2003009814A2 (en) | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US20050032065A1 (en) | 2002-06-24 | 2005-02-10 | Afar Daniel E. H. | Methods of prognosis of prostate cancer |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| EP1733047A2 (en) * | 2004-02-27 | 2006-12-20 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US7666595B2 (en) * | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| AU2006234897A1 (en) | 2005-03-16 | 2006-10-19 | Sidney Kimmel Cancer Center | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| JP2008538007A (ja) | 2005-04-15 | 2008-10-02 | ベクトン，ディッキンソン アンド カンパニー | 敗血症の診断 |
| EP1717320A1 (en) | 2005-04-26 | 2006-11-02 | TopoTarget Germany AG | Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy |
| EP1934367B1 (en) | 2005-09-14 | 2010-11-03 | National Research Council of Canada | Molecular method for diagnosis of prostate cancer |
| US20070059753A1 (en) | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| JP2009514555A (ja) | 2005-11-08 | 2009-04-09 | ユークリッド ダイアグノスティックス リミテッド ライアビリティー カンパニー | 癌評価の遺伝子関連ＣｐＧアイランドのメチル化アッセイのための材料と方法 |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20110045464A1 (en) | 2007-01-10 | 2011-02-24 | Henry Ford Health System | Methods and compositions for identification of prostate cancer markers |
| CA2680692A1 (en) | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2009151503A2 (en) | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| WO2009126271A1 (en) | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US20090298082A1 (en) | 2008-05-30 | 2009-12-03 | Klee George G | Biomarker panels for predicting prostate cancer outcomes |
| EP2315858A2 (en) | 2008-07-08 | 2011-05-04 | Source Precision Medicine, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
| AU2009270851A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute, Inc. | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof |
| US20100055705A1 (en) | 2008-08-29 | 2010-03-04 | Wilson Gerald M | Compositions and methods for diagnosing and treating cancer |
| US7888035B2 (en) | 2008-10-30 | 2011-02-15 | Caris Mpi, Inc. | Methods for assessing RNA patterns |
| CN102308212A (zh) | 2008-12-04 | 2012-01-04 | 加利福尼亚大学董事会 | 用于确定前列腺癌诊断和预后的材料和方法 |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| ES2700877T3 (es) | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| KR102110469B1 (ko) | 2009-05-12 | 2020-05-14 | 코닌클리케 필립스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
| WO2010139711A1 (en) | 2009-06-04 | 2010-12-09 | Metanomics Health Gmbh | Means and methods for diagnosing prostate carcinomas |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| EP2309273B1 (en) | 2009-09-16 | 2016-05-18 | ZEILLINGER, Robert | Novel tumor marker determination |
| WO2011068839A1 (en) | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| WO2011094233A1 (en) | 2010-01-26 | 2011-08-04 | The Johns Hopkins University | Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens |
| US20130058925A1 (en) | 2010-02-26 | 2013-03-07 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| CN105601727B (zh) | 2010-03-11 | 2020-01-10 | 肿瘤疗法科学股份有限公司 | Hjurp肽及包含它们的疫苗 |
| CA2836725A1 (en) | 2010-06-01 | 2011-12-08 | Indiana University Research And Technology Corporation | Materials and methods for diagnosing and predicting the course of prostate cancer |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US20130190310A1 (en) | 2010-07-26 | 2013-07-25 | The Johns Hopkins University | Mig6 and therapeutic efficacy |
| IL243203A (en) | 2010-07-27 | 2017-04-30 | Genomic Health Inc | Method for using gene expression to determine prognosis of prostate cancer |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| EP2702177B1 (en) | 2011-04-28 | 2017-04-12 | New York University | Genomic signatures of metastasis in prostate cancer |
| AU2012275500A1 (en) * | 2011-06-27 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with prostate cancer progression and methods of use thereof |
| US20130079241A1 (en) * | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| GB201206209D0 (en) | 2012-04-06 | 2012-05-23 | Univ Leuven Kath | Marker gene based diagnosis, staging and prognosis of prostate caner |
| AU2012358238B2 (en) | 2011-12-22 | 2017-12-07 | C. Frank Bennett | Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression |
| DK3179393T3 (da) | 2012-01-31 | 2020-07-27 | Genomic Health Inc | Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft |
| TW201343920A (zh) | 2012-03-29 | 2013-11-01 | 財團法人國家衛生研究院 | 預測前列腺癌預後之分子標記、方法與套組 |
| BR102012007246A2 (pt) | 2012-03-30 | 2016-02-10 | Fundação Antonio Prudente | métodos para prognóstico e classificação de resultados de um evento |
| US20130288967A1 (en) | 2012-04-25 | 2013-10-31 | Euclid Diagnostics Llc | Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8 |
| CN103146688B (zh) | 2012-09-12 | 2015-05-13 | 上海长海医院 | 长链非编码rna作为疾病诊断血液分子标志物的应用 |
-
2013
- 2013-12-12 GB GBGB1322034.8A patent/GB201322034D0/en not_active Ceased
-
2014
- 2014-12-12 EP EP14814697.0A patent/EP3080293B1/en active Active
- 2014-12-12 BR BR112016013182A patent/BR112016013182A2/pt not_active Application Discontinuation
- 2014-12-12 CN CN201480074318.2A patent/CN105940117A/zh active Pending
- 2014-12-12 US US15/103,770 patent/US10196697B2/en not_active Expired - Fee Related
- 2014-12-12 CA CA2932553A patent/CA2932553A1/en not_active Abandoned
- 2014-12-12 JP JP2016538689A patent/JP2017507320A/ja active Pending
- 2014-12-12 KR KR1020167018629A patent/KR20160098351A/ko not_active Withdrawn
- 2014-12-12 WO PCT/GB2014/053694 patent/WO2015087088A2/en not_active Ceased
- 2014-12-12 SG SG11201604508PA patent/SG11201604508PA/en unknown
- 2014-12-12 MX MX2016007333A patent/MX2016007333A/es unknown
- 2014-12-12 AU AU2014363173A patent/AU2014363173A1/en not_active Abandoned
-
2016
- 2016-06-06 IL IL246067A patent/IL246067A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507320A5 (enExample) | ||
| Van Treijen et al. | Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study | |
| Ogino et al. | Cancer immunology—analysis of host and tumor factors for personalized medicine | |
| Sun et al. | Serum microRNA-155 as a potential biomarker to track disease in breast cancer | |
| Spindler et al. | Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer | |
| Chen et al. | Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma | |
| Galván et al. | TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer | |
| Chundong et al. | Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis | |
| JP7157788B2 (ja) | 膵・消化管神経内分泌新生物の診断のための組成物、方法およびキット | |
| Xu-Welliver et al. | Blood-based biomarkers in lung cancer: prognosis and treatment decisions | |
| Bidard et al. | Translating metastasis-related biomarkers to the clinic—progress and pitfalls | |
| Sapre et al. | Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer | |
| Petrović et al. | The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion | |
| Schena et al. | DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients | |
| Kowalczyk et al. | SATB1 is down-regulated in clear cell renal cell carcinoma and correlates with miR-21-5p overexpression and poor prognosis | |
| JP2018527886A5 (enExample) | ||
| Bergot et al. | Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy | |
| Joerger et al. | Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy | |
| Netto | Molecular genetics and genomics progress in urothelial bladder cancer | |
| Gerhard et al. | Clinicopathological significance of ERCC1 expression in breast cancer | |
| McLaren et al. | Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma | |
| Berg et al. | Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study | |
| Chanida et al. | The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence | |
| JP2024170603A (ja) | 免疫チェックポイント阻害療法からの利益を予測する方法 | |
| Seyhan et al. | Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma |